Amneal Pharmaceuticals, Inc. (AMRX) Stock News
Follow the latest Amneal Pharmaceuticals, Inc. (AMRX) news and market headlines alongside the live AMRX price. Stay informed on what's moving AMRX.
News
Read Full Article - Read Full Article
'UK Drugmaker in Talks to Boost Estrogen Patch Supply in US' - Bloomberg
https://www.bloomberg.com/news/articles/2026-11-16/uk-drugmaker-in-talks-to-boost-estrogen-patch-supply-in-us
- Read Full Article
Here's Why You Should Add AURA Stock to Your Portfolio Now
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
- Read Full Article
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
- Read Full Article
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.
- Read Full Article
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
- Read Full Article
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV
Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to AMRX, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.

